- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00482443
Assessing the Effectiveness of Diabetes Interactive Diary (DID) in Diabetes Management (DID)
A Multinational, Randomised Study of the Efficacy of the Diabetes Interactive Diary (DID), a Carbohydrates/Insulin Bolus Calculator and a Telemedicine System Based on the Communication Between Physician or Dietitian and Patient by SMS
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is randomized control trial aimed to evaluate the effectiveness of a DID compare to the standard education approach in order to help the patients with Type 1 diabetes to estimate the carbohydrate in their food and adjust insulin doses. It involves individuals with Type 1 diabetes who are not habitually using carbohydrate counting. They should be testing their blood sugar levels at least 3 times a day, using multiple daily injections of short-acting and long-acting insulin analogues, with HbA1c between 7.5% and 10% and are familiar with the use of mobile phones and possess a personal SIM card.
Patients will be randomized to the standard education programme run for 4 full days over a 4 week period or to the DID programme run as three 2-hour sessions over a two-week period.
The DID is a novel software programme installed on the patient's mobile telephone. It facilitates the communication between the dietitian and the patient by using SMS text messages, so that the dietitian can monitor glycaemic control and suggest adjustments if necessary. It can be described as a little computer, where the patient can record their blood glucose value, the amount of insulin injected and the amount of carbohydrate consumed.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Dorset
-
Bournemouth, Dorset, United Kingdom, BH7 7DW
- Royal Bournemouth Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18 or over
- Not habitually using carbohydrate counting and insulin dose adjustment
- Testing their blood sugar levels at least 3 times a day
- Using multiple daily injections of short-acting and long-acting insulin analogues
- With HbA1c between 7.5% and 10%
- Familiar with the use of mobile phones and possess a personal SIM card.
Exclusion Criteria:
- Mental conditions, depression or high anxiety rendering the subject unable to understand the nature, scope, and possible consequences of the study
- Eating disorders
- Pregnancy
- Any clinically significant major organ system disease or infective diseases
- Any disease or condition or abuse of illicit drugs, prescription medicines or alcohol that in the opinion of the investigator may interfere with the completion of the study
- Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits and unlikely to complete the study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
To assess the efficacy of a Diabetes Interactive Diary in Diabetes Management.
|
Use of Mobile phone technology in maintaining Diabetes Interactive Diary.
|
Active Comparator: 2
Control Arm.
Patients will receive standard education programme.
|
Control Arm patients will receive a standard education programme designed to help the Type 1 Diabetic manage their condition.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The difference in HbA1c between the patient in the DID group and in the standard education group.
Time Frame: 6 month
|
6 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The differences between the two groups in terms of, lipid profile, blood pressure, the number of hypoglycaemic episodes, daily blood sugar fluctuation, total insulin dose, weight changes and patients' satisfaction with the treatment.
Time Frame: 6 month
|
6 month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David Kerr, Doctor, Royal Bournemouth Hospital
- Principal Investigator: Anita Bowes, Dietitian, Royal Bournemouth Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DID
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on A software programme in mobile telephone
-
Huawei Device Co., LtdRecruiting
-
Necmettin Erbakan UniversityRecruitingPulmonary Disease, Chronic ObstructiveTurkey
-
Weill Medical College of Cornell UniversityIthaca CollegeNot yet recruitingTransitioning Voice of Transgender and Gender Diverse PeopleUnited States
-
Universidad de GranadaAmgen; Fundación Pública Andaluza para la Investigación Biomédica Andalucía... and other collaboratorsNot yet recruiting
-
University Hospital, LilleCompleted
-
The Hong Kong Polytechnic UniversityNot yet recruitingMuscular Atrophy | Child With Cancer | Child With Cerebral Palsy | Child With Medical Complexity
-
Hospital Moinhos de VentoNot yet recruiting
-
University of WashingtonNational Institute of Dental and Craniofacial Research (NIDCR)Not yet recruiting
-
Fundació Institut de Recerca de l'Hospital de la...UnknownHeart Transplant
-
Beijing Airdoc Technology Co., Ltd.University of Notre Dame AustraliaRecruitingAstigmatism | Myopia | Myopia, ModerateChina